developing diagnostics for emerging and neglected infectious diseases

COVID-19 ANTIBODY TESTING BY KEPHERA NOW AVAILABLE

Kephera now offers COVID-19 antibody testing through its CLIA laboratory....details coming soon!

Latest News

About Us

Kephera Diagnostics is a startup that aims to address the public health challenges of global infectious diseases with point of care assay technology.  We collaborate with a global community of researchers to develop and translate new technologies into accessible products for clinical diagnostics and research applications.  Kephera has recently been funded for development of new tests for several infectious diseases of global significance.

Mission

Our mission is to promote more effective and more affordable medical treatment through faster, point-of-care diagnosis. 

Kephera’s goal is to accelerate the development of rapid, point-of-care tests for emerging infectious diseases to provide the critical diagnostic tools for medical and public health response in real-time, when and where they are most urgently needed.  We combine innovative technologies in molecular biology, immunology, chemistry and device engineering to develop novel diagnostics for this purpose.

Focus

Emerging infectious diseases are responsible for over one billion cases of illness every year and continue to be the leading cause of death worldwide.  Vector-borne diseases in particular, including malaria, dengue, Chagas, leishmania and others are major public health problems with over half of the world’s population at risk according to the World Health Organization.  Collectively, these diseases account for an annual global economic burden in the hundreds of billions of dollars. Fast and accurate diagnosis is the key to effective treatment for infectious diseases and to epidemiological monitoring on which intervention programs depend.  Diagnosis has traditionally relied on sophisticated laboratory tests, however, which are costly, complex, slow to develop, and not widely available. The unpredictability and speed with which many new infectious diseases emerge and spread makes the traditional approach unworkable – a recent example being the invasion of Zika virus in the western hemisphere in 2015.  Consequently, there is a critical need for the rapid development of diagnostics in accessible point-of-care formats that can timely and effectively address the global threat of emerging infectious diseases.

Team

Nadya Karaseva

Senior Scientist and R&D Project Manager

Cameron Friedman

Research Assistant
Gabrielle (Gabi) Farulla-Bastian
Research Assistant

Andrew Levin

Chief Executive Officer/Chief Scientific Officer

Jeremy Schonhorn

Director of Product Development

David Boyle

Business Manager

Vashti Irani

Research Scientist, Infectious Diseases

Leah Carlson

Research Associate

Hetali Shah

Research Associate

Careers

Kephera Diagnostics is a team of passionate scientists, working to brighten the future of diagnostics for emerging and neglected infectious diseases. Kephera seeks talented and enthusiastic team players inspired to make an impact on global public health by delivering better diagnostic information to patients at the point of care. Kephera offers a dynamic start-up environment combining flexibility, challenging work and the opportunity to participate in a new venture. Kephera is committed to a diverse workplace.

Open Positions

Business Development Manager

Read More

You will be the key person responsible for developing Kephera’s CLIA laboratory testing business, starting with a newly developed COVID-19 test.  In parallel, you will be responsible for developing the company’s product business, focusing on COVID-19 and other unique infectious disease and pathogen test kits, directly and through distribution.  You will interact closely with the R&D and CLIA laboratory teams.

Your qualifications should include business development/sales/marketing experience in the field of in vitro diagnostics, desirably in laboratory testing, with a solid technical understanding of infectious disease and pathogen testing technologies.  Experience with international markets is a plus.

Requires BA/BS and 3+ years of experience in business development/sales/marketing of in vitro diagnostic laboratory testing services or products in the area of infectious disease and pathogen testing.  Strong communication skills, technical background, entrepreneurial spirit desirable.

Scientist - Assay Development

Read More

Kephera seeks candidates for the position of assay development Scientist.  Responsibilities will include development and validation of immunoassays for a variety of infectious diseases, starting with COVID-19 and including others in a variety of formats including point-of-care and laboratory-based, documentation for product transfer, and participation in clinical studies for regulatory submission.

The successful candidate will possess a Ph.D. in biochemistry, molecular biology or other life science field and be well versed in biochemistry, molecular biology, microbiology and infectious diseases.  Your credentials should include significant assay development experience in the field of in vitro diagnostics, especially for infectious diseases.  Familiarity with immunoassays, rapid assays, conjugation techniques, protein purification and characterization, mammalian cell culture, recombinant protein construction and expression in bacterial and mammalian systems, pathogen biochemistry and microbiological methods is desirable. Strong laboratory and organizational skills, capability for independent problem-solving as well as teamwork, and excellent communication skills are essential.

Sales/Marketing Manager – In Vitro Diagnostics/Infectious Disease Testing

Read More

You will be the key person responsible for marketing and sales for Kephera’s CLIA laboratory testing business, starting with a newly developed COVID-19 test. The focus will expand to other unique infectious disease and pathogen test kits for laboratory testing. The successful candidate will develop and implement an effective sales and marketing strategy and manage client accounts. This position includes close interaction with the R&D and CLIA laboratory teams.

Required qualifications:

  • Sales/marketing experience in the field of in vitro diagnostics, desirably in laboratory testing, with a solid technical understanding of infectious disease and pathogen testing technologies.
  • BA/BS and 3+ years of experience in sales/marketing of in vitro diagnostic laboratory testing services or products in the area of infectious disease and pathogen testing.

Personal Skills:

  • Entrepreneurial spirit compatible with a fast-paced start-up
  • Strong communication and negotiation skills
  • Self-motivated, strategic and results-driven mindset
  • Team oriented workstyle

Technology

At Kephera, we are developing rapid tests for infectious diseases using novel immunochemistry in point-of-care format. Our proprietary assay technology is based on principles of particle interaction combined with a simple device, which together enable rapid detection of specific antibodies or antigens associated with the target pathogen. The broadly enabling technology is applicable to a wide range of disease targets and applications. Kephera’s expertise extends from antigen discovery using microarrays and peptide libraries to assay development, clinical studies and validation. We work with some of the leading academic research institutions in the U.S. and internationally, along with researchers at the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC).

Product Pipeline

Diagnostic Test for Zika Virus Infection

Kephera is developing a test for Zika virus infection with support from a grant from the National Institutes of Health. Kephera’s Zika project is based on the identification of Zika-specific and Dengue-specific epitopes within the viral genome, from which an immunoassay will be developed in convenient and cost-effective ELISA format, and ultimately translated to point-of-care format.  To this end, we are working in collaboration with medical research institutes in the U.S. and Latin America to analyze the immunological reactivities of patient sera from Zika and Dengue-endemic regions, using a variety of epitope mapping techniques. Epitopes selected based on ability to differentiate viral infections will then be expressed synthetically or as recombinant antigens for assay development.

What is Zika?

Zika emerged in 2015 as a major public health threat in the western hemisphere, leading to an urgent need for diagnostic tools for clinical and epidemiological use. Although primary Zika infection is typically accompanied by mild symptoms, the virus has been linked to severe birth defects in infants born to infected mothers, and to potentially fatal neurological conditions including Guillain Barré syndrome.

How Does it Spread?

Zika is transmitted by the same Aedes mosquito species that transmit the related Dengue and Yellow Fever viruses, along with a variety of others such as Chikungunya.  As Dengue virus is endemic in much of the tropical world, background immunological reactivity to Dengue tends to confound the serological diagnosis of Zika infection.  Accurate diagnosis of Zika infection in the post-viremic or convalescent phase continues to be a significant challenge, calling for the development of tests which are truly specific for this virus.

How is it Diagnosed?

Zika infection can be detected by molecular assays, but this approach is only useful during the relatively brief viremic phase, typically several weeks or less. After this period, individuals including pregnant women at risk for complications caused by prior infection can only be identified by serologic assays. The close genetic relationship between Zika and other flaviviruses has made serological diagnosis extremely difficult, however, due to cross-reactivities between viral antigens.

Chagas Disease - Rapid Test

With support from a National Institutes of Health grant, Kephera is developing a new point-of-care test for Chagas disease.  Kephera scientists have identified and are purifying parasite components which promise to yield a highly sensitive and specific test.  Together with our academic collaborators in the U.S. and Latin America, we are evaluating the performance of the test as it is developed in our laboratory.

What is Chagas?

Chagas disease, a chronic infection with the parasite Trypanosoma cruzi, is the most prevalent parasitic disease in the western hemisphere, outranking even malaria. Because the disease can be asymptomatic for a long period of time, often years, most cases are not detected until the chronic stage. In the interim, infected individuals remain – most unknowingly – T. cruzi carriers.  Infection can cause severe gastrointestinal and cardiac disease, and cardiomyopathy leading to early death is a major cause of lost productivity. The global economic burden of Chagas disease is estimated at $7-19 billion/year.  Consequently, the World Health Organization (WHO) has identified Chagas disease as a top priority for public health intervention.

How Does it Spread?

Chagas disease is endemic to large regions of Latin America, where it is transmitted to humans by the triatomid bug.  Transmission can also occur through blood transfusion, organ transplant and congenitally. More than 70 million people live at risk, resulting in over 10 million infections.

How is it Currently Diagnosed?

Chagas disease can be diagnosed through the detection of antibodies to the parasite in a patient’s blood.  A variety of antibody tests have been developed, with varying performance. Because the sensitivity as well as the specificity of serologic tests can be compromised by cross-reactive antigens and by genetic diversity among T. cruzi strains, the current diagnostic approach relies on comparing and combining the results of multiple independent tests.  The shortcomings of the current generation of tests in sensitivity or specificity point to the need for newer, more accurate tests, which can preferably be carried out outside a laboratory.

Lyme disease - Diagnostic Test

OLYMPUS DIGITAL CAMERA

Kephera is developing a new test for Lyme disease, supported by a grant from the National Institute of Allergy and Infectious Diseases.  Lyme disease has become the most common vector-borne disease in the U.S., with over 300,000 cases per year estimated by epidemiologists.  It is a risk throughout large parts of the U.S., northern Europe and Asia.  Lyme disease presents a diagnostic challenge due to the overlap in symptoms with other disease conditions.  We are collaborating with public health agencies and medical centers that treat Lyme patients to develop a new test based on innovative technology that could improve the accuracy of diagnosis of Lyme disease.

What is Lyme Disease?

Lyme disease is caused by infection with the spirochetal bacterium Borrelia burgdorferior one of its close relatives, which are transmitted by deer ticks.  The bacteria initially spread through the skin, producing the characteristic bull’s eye rash in many patients, and often a flu-like illness. If untreated, the bacteria can disseminate within the body, causing neurological, arthritic, cardiac or other serious and debilitating symptoms.  If detected early, antibiotic treatment can be highly effective.  However, as the disease progresses, treatment can become more challenging.

borrelia2
Ixodes scapularis tick 2

How Does it Spread?

Lyme disease is transmitted by deer ticks, which inhabit grassy and woodland areas where deer and mice, their natural hosts, live.  Humans are accidental victims.  The pinhead-sized deer tick may not be seen or felt, and many people are unaware that they have been infected until symptoms appear.

How is it Diagnosed?

The circular bull’s eye rash is the hallmark of a Lyme disease infection in its early stages.  But the rash is not always seen, and the symptoms that appear later are more non-specific and may resemble other disease conditions.  To diagnose such cases, current practice calls for a two-step testing protocol. Patients are tested for antibodies to the Lyme spirochete by a screening test, and results confirmed by immunoblot, a second, more specific test.  This approach has been recommended since 1995.  However, it has been shown to be relatively insensitive in early stages of Lyme disease, and relies on immunoblot which is a subjective, labor-intensive method of limited availability.  Accordingly, there is a growing need for more sensitive and accessible testing methods for Lyme disease.  Kephera aims to provide a solution to this need through the new test under development.

Bullseye_Lyme_Disease_Rash

News

Kephera Diagnostics awarded Phase II grant from the National Institute of Allergy and Infectious Diseases (NAID) for Zika virus test

Kephera Diagnostics awarded Phase II grant from the National Institute of Allergy and Infectious Diseases (NAID) for Zika virus test Framingham, MA – July 23, 2020. Kephera Diagnostics announced today that it has been awarded a two-year, $1,989,300 Phase II Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases…

Read more

Kephera seeks volunteers who are confirmed COVID-19 positive to donate finger prick blood samples to help develop a new COVID-19 antibody test.

Kephera seeks volunteers who are confirmed COVID-19 positive to donate finger prick blood samples to help develop a new COVID-19 antibody test. Framingham, MA, April 24, 2020…….Kephera Diagnostics has launched a new study aimed at collecting blood samples from  volunteers at least 18 years of age who have been confirmed positive for COVID-19, for use…

Read more

Contact Us

Email:

Address:

Kephera Diagnostics, LLC

1 Grant Street, Suite 300

Framingham, MA 01702